Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Identification of molecular markers at either the intragenic, chromosomal, mRNA, or protein level that might predict whether colorectal cancer patients are likely to benefit from adjuvant or palliative therapy is a high priority. The majority of clinical studies addressing this issue, particularly those done in the adjuvant setting, analyzed tumor samples from patients treated in the era when 5-fluorouracil (5-FU) alone or combined with leucovorin or levamisole were the mainstay of therapy. This review highlights some of the intratumoral molecular markers that may have importance as predictors of benefit with 5-FU-based therapy. Although the goal of these investigations is to one day permit selection of therapy for an individual patient based on the tumor phenotype, prospective studies have yet to be conducted that test whether selection of therapy based on molecular markers results in an improved outcome.

Original languageEnglish (US)
Pages (from-to)120-127
Number of pages8
JournalSeminars in Oncology
Volume32
Issue number1 SPEC. ISS.
DOIs
StatePublished - Jan 1 2005

Fingerprint

Genetic Markers
Molecular Biology
Colorectal Neoplasms
Drug Therapy
Fluorouracil
Levamisole
Leucovorin
Therapeutics
Palliative Care
Neoplasms
Prospective Studies
Phenotype
Messenger RNA
Proteins

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. / Grem, Jean L.

In: Seminars in Oncology, Vol. 32, No. 1 SPEC. ISS., 01.01.2005, p. 120-127.

Research output: Contribution to journalArticle

@article{6d166ab319c1465cbc324f5c48297c10,
title = "Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer",
abstract = "Identification of molecular markers at either the intragenic, chromosomal, mRNA, or protein level that might predict whether colorectal cancer patients are likely to benefit from adjuvant or palliative therapy is a high priority. The majority of clinical studies addressing this issue, particularly those done in the adjuvant setting, analyzed tumor samples from patients treated in the era when 5-fluorouracil (5-FU) alone or combined with leucovorin or levamisole were the mainstay of therapy. This review highlights some of the intratumoral molecular markers that may have importance as predictors of benefit with 5-FU-based therapy. Although the goal of these investigations is to one day permit selection of therapy for an individual patient based on the tumor phenotype, prospective studies have yet to be conducted that test whether selection of therapy based on molecular markers results in an improved outcome.",
author = "Grem, {Jean L}",
year = "2005",
month = "1",
day = "1",
doi = "10.1053/j.seminoncol.2004.09.027",
language = "English (US)",
volume = "32",
pages = "120--127",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SPEC. ISS.",

}

TY - JOUR

T1 - Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer

AU - Grem, Jean L

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Identification of molecular markers at either the intragenic, chromosomal, mRNA, or protein level that might predict whether colorectal cancer patients are likely to benefit from adjuvant or palliative therapy is a high priority. The majority of clinical studies addressing this issue, particularly those done in the adjuvant setting, analyzed tumor samples from patients treated in the era when 5-fluorouracil (5-FU) alone or combined with leucovorin or levamisole were the mainstay of therapy. This review highlights some of the intratumoral molecular markers that may have importance as predictors of benefit with 5-FU-based therapy. Although the goal of these investigations is to one day permit selection of therapy for an individual patient based on the tumor phenotype, prospective studies have yet to be conducted that test whether selection of therapy based on molecular markers results in an improved outcome.

AB - Identification of molecular markers at either the intragenic, chromosomal, mRNA, or protein level that might predict whether colorectal cancer patients are likely to benefit from adjuvant or palliative therapy is a high priority. The majority of clinical studies addressing this issue, particularly those done in the adjuvant setting, analyzed tumor samples from patients treated in the era when 5-fluorouracil (5-FU) alone or combined with leucovorin or levamisole were the mainstay of therapy. This review highlights some of the intratumoral molecular markers that may have importance as predictors of benefit with 5-FU-based therapy. Although the goal of these investigations is to one day permit selection of therapy for an individual patient based on the tumor phenotype, prospective studies have yet to be conducted that test whether selection of therapy based on molecular markers results in an improved outcome.

UR - http://www.scopus.com/inward/record.url?scp=13844289422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844289422&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.09.027

DO - 10.1053/j.seminoncol.2004.09.027

M3 - Article

VL - 32

SP - 120

EP - 127

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SPEC. ISS.

ER -